Shin Nippon Biomedical Laboratories, Ltd. (FRA:YB3)
Germany · Delayed Price · Currency is EUR 10.00
+0.50 (5.26%)
At close: Nov 28, 2025
FRA:YB3 Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Net Income | 5,581 | 6,013 | 6,974 | 7,759 | 8,183 | 4,175 | Upgrade |
Depreciation & Amortization | 3,033 | 2,610 | 1,867 | 1,600 | 1,177 | 1,187 | Upgrade |
Loss (Gain) From Sale of Assets | 514 | 306 | 84 | 56 | 246 | 642 | Upgrade |
Loss (Gain) From Sale of Investments | 168 | 147 | 31 | 1,321 | -1,058 | -1,173 | Upgrade |
Loss (Gain) on Equity Investments | -2,994 | -3,513 | -2,751 | -2,489 | -1,439 | -846 | Upgrade |
Other Operating Activities | 321 | 350 | 1,048 | 256 | -90 | -66 | Upgrade |
Change in Accounts Receivable | 301 | -870 | -956 | -937 | -480 | -343 | Upgrade |
Change in Inventory | 1,375 | -149 | -5,003 | -968 | -371 | -71 | Upgrade |
Change in Accounts Payable | -148 | -9 | -177 | -268 | -36 | -24 | Upgrade |
Change in Other Net Operating Assets | 472 | 2,150 | 989 | -2,326 | -180 | 1,265 | Upgrade |
Operating Cash Flow | 8,623 | 7,035 | 2,106 | 4,004 | 5,952 | 4,746 | Upgrade |
Operating Cash Flow Growth | 422.61% | 234.05% | -47.40% | -32.73% | 25.41% | 57.26% | Upgrade |
Capital Expenditures | -6,445 | -10,853 | -8,582 | -4,838 | -1,542 | -1,067 | Upgrade |
Sale of Property, Plant & Equipment | 8 | 4 | 5 | 11 | - | 1 | Upgrade |
Cash Acquisitions | - | - | -883 | -1,937 | 58 | - | Upgrade |
Divestitures | - | - | - | - | 1,142 | 1,242 | Upgrade |
Sale (Purchase) of Intangibles | -90 | -79 | -22 | -116 | -71 | -50 | Upgrade |
Investment in Securities | -1,792 | -771 | 2,625 | 1,018 | -4,194 | -804 | Upgrade |
Other Investing Activities | 4 | 8 | -50 | -68 | 2 | -1 | Upgrade |
Investing Cash Flow | -8,315 | -11,691 | -6,907 | -5,930 | -4,268 | -268 | Upgrade |
Short-Term Debt Issued | - | 2,916 | - | 4,083 | - | - | Upgrade |
Long-Term Debt Issued | - | 14,000 | 17,700 | 10,300 | - | 4,540 | Upgrade |
Total Debt Issued | 11,536 | 16,916 | 17,700 | 14,383 | - | 4,540 | Upgrade |
Short-Term Debt Repaid | - | - | -3,903 | - | -6 | -2,000 | Upgrade |
Long-Term Debt Repaid | - | -8,827 | -6,231 | -5,469 | -3,492 | -4,598 | Upgrade |
Total Debt Repaid | -8,824 | -8,827 | -10,134 | -5,469 | -3,498 | -6,598 | Upgrade |
Net Debt Issued (Repaid) | 2,712 | 8,089 | 7,566 | 8,914 | -3,498 | -2,058 | Upgrade |
Common Dividends Paid | -2,101 | -2,100 | -2,073 | -2,485 | -827 | -207 | Upgrade |
Other Financing Activities | -69 | -75 | -175 | -163 | -586 | -206 | Upgrade |
Financing Cash Flow | 542 | 5,914 | 5,318 | 6,266 | -4,911 | -2,471 | Upgrade |
Foreign Exchange Rate Adjustments | -479 | 369 | 559 | 311 | 496 | 29 | Upgrade |
Miscellaneous Cash Flow Adjustments | -58 | -58 | 1 | -2 | - | - | Upgrade |
Net Cash Flow | 313 | 1,569 | 1,077 | 4,649 | -2,731 | 2,036 | Upgrade |
Free Cash Flow | 2,178 | -3,818 | -6,476 | -834 | 4,410 | 3,679 | Upgrade |
Free Cash Flow Growth | - | - | - | - | 19.87% | 96.74% | Upgrade |
Free Cash Flow Margin | 6.28% | -11.78% | -24.48% | -3.32% | 24.85% | 24.35% | Upgrade |
Free Cash Flow Per Share | 52.32 | -91.71 | -155.56 | -20.03 | 105.93 | 88.37 | Upgrade |
Cash Interest Paid | 248 | 216 | 125 | 118 | 118 | 172 | Upgrade |
Cash Income Tax Paid | 2,162 | 2,013 | 1,223 | 1,437 | 1,014 | 479 | Upgrade |
Levered Free Cash Flow | -1,354 | -5,525 | -7,430 | -2,725 | 2,467 | 2,677 | Upgrade |
Unlevered Free Cash Flow | -1,207 | -5,398 | -7,344 | -2,647 | 2,546 | 2,792 | Upgrade |
Change in Working Capital | 2,000 | 1,122 | -5,147 | -4,499 | -1,067 | 827 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.